Neurimmune Holding Ag

University of Zürich

Santhera Pharmaceuticals Ag

Fabrice Heitz

Jan Grimm

Achim Feurer

Feng Chen

Ioana Combaluzier

Tobias Welt

Fabian Wirth

Barbara Hoffmann-Enger

Roman Haefeli

Holger Deppe

Michael Erb

Robert Dallmann

Nuri Gueven

Provided are novel human islet amyloid polypeptide, also known as amylin and IAPP and proIAPP respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for IAPP and/or proIAPP are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for IAPP and/or proIAPP targeted immunotherapy and diagnostics, respectively.

Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof

Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced &#x3b2;-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).

Compounds capable of antagonizing islet amyloid polypeptide (IAPP) induced beta-cell damage and impaired glucose tolerance

Human islet amyloid polypeptide (HIAPP) specific antibodies and uses thereof

Growing community of inventors

Bartenheim, France

Fabrice Heitz